PMID- 35709779
OWN - NLM
STAT- MEDLINE
DCOM- 20220620
LR  - 20220620
IS  - 1784-3227 (Print)
IS  - 1784-3227 (Linking)
VI  - 85
IP  - 2
DP  - 2022 Apr-Jun
TI  - Non-invasive screening, staging and management of metabolic 
      dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus 
      patients: what do we know so far ?
PG  - 346-357
LID - 10.51821/85.2.9775 [doi]
AB  - Metabolic dysfunction-associated fatty liver disease (MAFLD) is the evidence of 
      steatosis in the setting of a metabolic risk condition such as type 2 diabetes 
      mellitus (T2DM). Indeed, T2DM and liver steatosis share common pathophysiological 
      mechanisms, and one can lead to the other. MAFLD can progress from simple 
      steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis as well 
      as hepatocellular carcinoma (HCC). Because of the lack / disparity of guidelines 
      for MAFLD screening, which is asymptomatic in its early stages, it is not rare 
      that diabetic patients are belatedly diagnosed with NASH cirrhosis or HCC. We 
      therefore recommend systematic non-invasive tests (NITs) that calculate an 
      estimate of the risk based on readily available anthropometric and biological 
      parameters. These include the fatty liver index (FLI) for steatosis detection and 
      at least one of the following for fibrosis: non-alcoholic fatty liver disease 
      fibrosis score (NFS), fibrosis-4 index (FIB-4) or Hepamet fibrosis score (HFS). 
      Indeed, NFS and FIB-4 are the best predictors of liver-related events, while 
      FIB-4 and HFS correlate with overall mortality. Systematic literature review 
      found only few retrospective or cross-sectional studies using NITs for systematic 
      steatosis and fibrosis screening in T2DM patients, with a crucial need for 
      prospective studies. This screening strategy will allow targeted patients to be 
      referred for further liver investigation (e.g. ultrasound, elastometry) and care. 
      Current treatment modalities of MAFLD in T2DM patients range from lifestyle and 
      dietary interventions to specific glucose-lowering drugs that recently showed 
      some benefits regarding MAFLD, such as pioglitazone, glucagon-like peptide-1 
      receptor agonists and sodium-glucose cotransporter-2 inhibitors. Other treatments 
      are currently under investigation.
CI  - (c) Acta Gastro-Enterologica Belgica.
FAU - Binet, Q
AU  - Binet Q
AD  - Service d'Hepato-Gastroenterologie, Cliniques universitaires Saint-Luc, 
      UCLouvain, Brussels, Belgium.
FAU - Loumaye, A
AU  - Loumaye A
AD  - Service d'Endocrinologie et Nutrition, Cliniques universitaires Saint-Luc, 
      UCLouvain, Brussels, Belgium.
FAU - Preumont, V
AU  - Preumont V
AD  - Service d'Endocrinologie et Nutrition, Cliniques universitaires Saint-Luc, 
      UCLouvain, Brussels, Belgium.
FAU - Thissen, J P
AU  - Thissen JP
AD  - Service d'Endocrinologie et Nutrition, Cliniques universitaires Saint-Luc, 
      UCLouvain, Brussels, Belgium.
FAU - Hermans, M P
AU  - Hermans MP
AD  - Service d'Endocrinologie et Nutrition, Cliniques universitaires Saint-Luc, 
      UCLouvain, Brussels, Belgium.
FAU - Lanthier, N
AU  - Lanthier N
AD  - Service d'Hepato-Gastroenterologie, Cliniques universitaires Saint-Luc, 
      UCLouvain, Brussels, Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - Belgium
TA  - Acta Gastroenterol Belg
JT  - Acta gastro-enterologica Belgica
JID - 0414075
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Glucose/therapeutic use
MH  - Humans
MH  - Liver Cirrhosis/complications/diagnosis/therapy
MH  - *Liver Neoplasms/drug therapy
MH  - *Non-alcoholic Fatty Liver Disease/complications/diagnosis/therapy
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
OTO - NOTNLM
OT  - MAFLD
OT  - NAFLD
OT  - NASH
OT  - non-invasive tests
OT  - type 2 diabetes
COIS- The authors declare that they have no conflict of interest
EDAT- 2022/06/17 06:00
MHDA- 2022/06/22 06:00
CRDT- 2022/06/16 18:59
PHST- 2022/06/16 18:59 [entrez]
PHST- 2022/06/17 06:00 [pubmed]
PHST- 2022/06/22 06:00 [medline]
AID - 10.51821/85.2.9775 [doi]
PST - ppublish
SO  - Acta Gastroenterol Belg. 2022 Apr-Jun;85(2):346-357. doi: 10.51821/85.2.9775.